Wall Street analysts expect Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) to post earnings of ($0.34) per share for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Tetraphase Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($0.40). Tetraphase Pharmaceuticals reported earnings of ($0.63) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 46%. The business is expected to issue its next quarterly earnings results on Thursday, November 1st.
On average, analysts expect that Tetraphase Pharmaceuticals will report full-year earnings of ($1.38) per share for the current year, with EPS estimates ranging from ($1.82) to ($1.05). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.14) per share, with EPS estimates ranging from ($1.77) to ($0.77). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.18. Tetraphase Pharmaceuticals had a negative return on equity of 67.34% and a negative net margin of 421.64%. The business had revenue of $11.58 million during the quarter, compared to the consensus estimate of $2.23 million.
A number of brokerages recently issued reports on TTPH. ValuEngine raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Friday, August 3rd. B. Riley upped their price target on Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, August 28th. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a report on Thursday, August 2nd. Finally, HC Wainwright upped their price target on Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, August 28th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company. Tetraphase Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $6.41.
Shares of TTPH opened at $3.14 on Friday. The company has a market capitalization of $170.21 million, a P/E ratio of -1.19 and a beta of 2.65. Tetraphase Pharmaceuticals has a 52-week low of $2.05 and a 52-week high of $7.98.
Several hedge funds have recently bought and sold shares of TTPH. Flagship Harbor Advisors LLC acquired a new stake in shares of Tetraphase Pharmaceuticals in the second quarter valued at approximately $104,000. Cubist Systematic Strategies LLC boosted its holdings in shares of Tetraphase Pharmaceuticals by 232.1% in the second quarter. Cubist Systematic Strategies LLC now owns 35,537 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 24,837 shares during the period. Canada Pension Plan Investment Board acquired a new stake in shares of Tetraphase Pharmaceuticals in the second quarter valued at approximately $179,000. Dynamic Technology Lab Private Ltd boosted its holdings in shares of Tetraphase Pharmaceuticals by 322.1% in the first quarter. Dynamic Technology Lab Private Ltd now owns 76,108 shares of the biopharmaceutical company’s stock valued at $234,000 after acquiring an additional 58,079 shares during the period. Finally, Alambic Investment Management L.P. acquired a new stake in shares of Tetraphase Pharmaceuticals in the first quarter valued at approximately $356,000. 40.94% of the stock is owned by institutional investors and hedge funds.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Featured Story: Tariff
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.